Welcome to LookChem.com Sign In|Join Free

CAS

  • or
L-erythro-Ritalinic Acid, also known as a single enantiomer of erythro Ritalinic acid (R533100), is a chiral compound derived from the erythro Ritalinic acid family. It possesses unique stereochemical properties that make it valuable in various applications, particularly in the field of chemistry and pharmaceuticals.

1076192-92-1 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1076192-92-1 Structure
  • Basic information

    1. Product Name: L-erythro-Ritalinic Acid
    2. Synonyms: L-erythro-Ritalinic Acid;(αR,2S)-α-Phenyl-2-piperidineacetic Acid
    3. CAS NO:1076192-92-1
    4. Molecular Formula: C13H17NO2
    5. Molecular Weight: 219.27958
    6. EINECS: N/A
    7. Product Categories: Aromatics;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals
    8. Mol File: 1076192-92-1.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: L-erythro-Ritalinic Acid(CAS DataBase Reference)
    10. NIST Chemistry Reference: L-erythro-Ritalinic Acid(1076192-92-1)
    11. EPA Substance Registry System: L-erythro-Ritalinic Acid(1076192-92-1)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1076192-92-1(Hazardous Substances Data)

1076192-92-1 Usage

Uses

Used in Chiral Separation:
L-erythro-Ritalinic Acid is used as a component for creating enantioselective stationary phases, which are crucial in the separation and analysis of enantiomers. These phases play a significant role in the pharmaceutical industry for the development and quality control of chiral drugs, ensuring the purity and efficacy of the desired enantiomer.
Used in Pharmaceutical Industry:
L-erythro-Ritalinic Acid is used as a single enantiomer of erythro Ritalinic acid (R533100) in the pharmaceutical industry. The importance of enantiomers lies in their distinct biological activities, which can lead to different therapeutic effects or side effects. By utilizing L-erythro-Ritalinic Acid as a single enantiomer, researchers can develop more targeted and effective drugs with reduced side effects.

Check Digit Verification of cas no

The CAS Registry Mumber 1076192-92-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,7,6,1,9 and 2 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1076192-92:
(9*1)+(8*0)+(7*7)+(6*6)+(5*1)+(4*9)+(3*2)+(2*9)+(1*2)=161
161 % 10 = 1
So 1076192-92-1 is a valid CAS Registry Number.

1076192-92-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name (2R)-2-phenyl-2-[(2S)-piperidin-2-yl]acetic acid

1.2 Other means of identification

Product number -
Other names L-erythro-Ritalinic Acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1076192-92-1 SDS

1076192-92-1Relevant articles and documents

Preparation and structural analysis of (±)-threo-ritalinic acid

Wyss, Sara,Werner, Irmgard A.,Schweizer, W. Bernd,Ametamey, Simon M.,Milicevic Sephton, Selena

, (2013)

Hydrolysis of the methyl ester (±)-threo-methyl phenidate afforded the free acid in 40% yield, viz. (±)-threo-ritalinic acid, C 13H17NO2. Hydrolysis and subsequent crystallization were accomplished at pH values between 5 a

Enzymatic resolution of (±)-threo-methylphenidate

Prashad, Mahavir,Har, Denis,Repic, Oljan,Blacklock, Thomas J.,Giannousis, Peter

, p. 2133 - 2136 (1998)

The resolution of (±)-threo-methylphenidate by enzymatic hydrolysis with α-chymotrypsin or subtilisin carlsberg to afford (2S,2'S)-(-)-threo and (2R,2'R)-(+)-threo-methylphenidate hydrochlorides in high enantiomeric purities is described.

AN IMPROVED PROCESS FOR THE PREPARATION OF DEXMETHYL PHENIDATE HYDROCHLORIDE

-

Page/Page column 8; 9, (2018/02/28)

Disclosed herein a process for the preparation of highly pure dexmethylphenidate hydrochloride (Formula-I) which comprises the steps of neutralization of dl- threomethylphenidate hydrochloride to dl-threo methylphenidate; subsequent resolution of dl-threo methylphenidate using amino acid or its derivatives as chiral resolution agent to yield dexmethylphenidate salt; hydrolysis of the salt and further conversion of dexmethylphenidate into its hydrochloride salt.

Microtubing-Reactor-Assisted Aliphatic C?H Functionalization with HCl as a Hydrogen-Atom-Transfer Catalyst Precursor in Conjunction with an Organic Photoredox Catalyst

Deng, Hong-Ping,Zhou, Quan,Wu, Jie

, p. 12661 - 12665 (2018/09/20)

Chlorine radical, which is classically generated by the homolysis of Cl2 under UV irradiation, can abstract a hydrogen atom from an unactivated C(sp3)?H bond. We herein demonstrate the use of HCl as an effective hydrogen-atom-transfer catalyst precursor activated by an organic acridinium photoredox catalyst under visible-light irradiation for C?H alkylation and allylation. The key to success relied on the utilization of microtubing reactors to maintain the volatile HCl catalyst. This photomediated chlorine-based C?H activation protocol is effective for a variety of unactivated C(sp3)?H bond patterns, even with primary C(sp3)?H bonds, as in ethane. The merit of this strategy is illustrated by rapid access to several pharmaceutical drugs from abundant unfunctionalized alkane feedstocks.

PROCESS FOR PREPARING METHYL PHENIDATE HYDROCHLORIDE

-

Page/Page column 5-6, (2011/06/25)

Disclosed herein is a process for the preparation of methyl phenidate hydrochloride (Formula I), comprising the steps of; hydrolyzing α-phenyl-α-pipyridyl acetamide (Formula II) in presence of mineral acid at reflux temperature and subsequent neutralization to yield threo -α-phenyl-α-pipyridyl-2-acetic acid (Formula III) which in presence of acidic catalyst reacts with methanol followed by treatment with alcoholic hydrochloride solution produces methyl phenidate hydrochloride.

A PROCESS FOR THE PREPARATION OF ALPHA-ARYL-ALPHA-PIPERID-2-YL-ACETAMIDES AND THE ACID HYDROLYSIS THEREOF

-

Page/Page column 5, (2008/06/13)

A process for the preparation of -aryl--piperid-2-yl-acetamides of formula (I) in which Ar is as defined in the disclosure, by catalytic reduction of α-aryl-α-pyridin-2-yl-acetamides (II) with rhodium catalysts. Acetamides of formula (II) can subsequently by hydrolysed to the corresponding arylacetic acids, e. g. ritalinic acid, a direct precursor of methylphenidate.

Method to separate stereoisomers

-

Page/Page column 3-4, (2010/02/13)

A method to resolve the stereoisomers of an optically active compound comprising an amine moiety. The method provides a mixture comprising two stereoisomers of a compound comprising a amine moiety. The method supplies l-fenchyloxyacetic acid, treats the mixture of stereoisomers with that l-fenchyloxyacetic acid, and collects one of those two stereoisomers having greater than a 99 percent enantiomeric excess.

Synthesis and pharmacology of potential cocaine antagonists. 2. Structure-activity relationship studies of aromatic ring-substituted methylphenidate analogs

Deutsch, Howard M.,Shi, Qing,Gruszecka-Kowalik, Ewa,Schwer, Margaret M.

, p. 1201 - 1209 (2007/10/03)

As part of a program, to develop medications which can block the binding of cocaine to the dopamine transporter, yet spare dopamine uptake, a series of aromatic ring-substituted methylphenidate derivatives was synthesized and tested for inhibitory potency in [3H]WIN 35,428 binding and [3H]dopamine uptake assays using rat striatal tissue. Synthesis was accomplished by alkylation of 2-bromopyridine with anions derived from various substituted phenylacetonitriles. In most cases, erythro compounds were markedly less potent than the corresponding (±)-threo-methylphenidate (TMP; Ritalin) derivatives. The ortho-substituted compounds were much less potent than the corresponding meta- and/or para-substituted derivatives. The most potent compound against [3H]WIN 35,428 binding, m-bromo-TMP, was 20-fold more potent than the parent compound, whereas the most potent compound against [3H]dopamine uptake, m,p-dichloro-TMP, was 32-fold more potent. Threo derivatives with m-or p-halo substituents were more potent than TMP, while electron-donating substituants caused little change or a small loss of potency. All of the derivatives had Hill coefficients approaching unity, except m,p-dichloro-TMP, which had an nH of 2.0. Although the potency of the (±)-methylphenidate derivatives in the two assays was highly correlated (R2 = 0.986), the compounds m-chloro-, m-methyl-, and p-iodo-TMP were 4-5-fold more potent at inhibiting [3H]-WIN 35,428 binding than [3H]dopamine uptake (cocaine has a ratio of 2.3). These and other compounds may be promising candidates for further testing as potential partial agonists or antagonists of cocaine.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1076192-92-1